<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14265">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00319553</url>
  </required_header>
  <id_info>
    <org_study_id>Td516</org_study_id>
    <nct_id>NCT00319553</nct_id>
  </id_info>
  <brief_title>Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®</brief_title>
  <official_title>Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACEL™ and BOOSTRIX®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a descriptive study to evaluate the safety and immunogenicity of ADACEL® and
      BOOSTRIX® vaccines among US adolescents.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Participants Reporting A Solicited Injection Site or Systemic Reactions Within 7 Days Following Vaccination With Adacel® or Boostrix®</measure>
    <time_frame>Day 0 to 7 post-vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited injection site reactions: Pain, Erythema, and swelling. Solicited systemic reactions: Fever (temperature), Headache, Malaise, and Myalgia.
Grade 3 reaction definitions: Pain = Incapacitating, unable to perform usual activities; Erythema and swelling = ≥ 5 cm; Fever = temperature ≥ 39.1°C or ≥ 102.3°F; Headache, Malaise, and Myalgia = Prevents daily activities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Tetanus Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination With Adacel® or Boostrix®.</measure>
    <time_frame>Day 0 and 28 days post-vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Diphtheria Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination With Adacel® or Boostrix®.</measure>
    <time_frame>Day 0 and 28 days post-vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Antibody to Pertussis Antigens Pre- and Post-Vaccination With Adacel® or Boostrix®.</measure>
    <time_frame>Day 0 and 28 days post-vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">647</enrollment>
  <condition>Pertussis</condition>
  <condition>Tetanus</condition>
  <condition>Diphtheria</condition>
  <arm_group>
    <arm_group_label>Adacel® Vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BOOSTRIX® Vaccine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>Adacel® Vaccine Group</arm_group_label>
    <other_name>ADACEL®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>BOOSTRIX® Vaccine Group</arm_group_label>
    <other_name>BOOSTRIX®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 11 - 18 years of age at the time of vaccination in this trial

          -  Signed Institutional Review Board (IRB)-approved informed assent / consent form.

          -  Able to attend all scheduled visits and to comply with all trial procedures.

          -  For a female, negative serum/urine pregnancy test.

        Exclusion Criteria:

          -  Any condition which, in the opinion of the investigator, would pose a health risk to
             the participant or interfere with the evaluation of the vaccine.

          -  Serious chronic disease (i.e. cardiac, renal, neurologic, metabolic, rheumatologic,
             psychiatric etc) that is unstable or that might:

               -  interfere with the ability to participate fully in the study; or

               -  interfere with evaluation of the vaccine.

          -  Known or suspected impairment of immunologic function.

          -  Febrile illness within the last 72 hours or an oral temperature ≥ 100.4°F (≥ 38°C) at
             the time of inclusion.

          -  History of documented tetanus, diphtheria or pertussis disease within the preceding 5
             years.

          -  Known or suspected receipt of a tetanus or diphtheria-containing vaccine within the
             preceding 2 years.

          -  Known or suspected receipt of a pertussis-containing vaccine within the preceding 5
             years.

          -  Administration of immune globulin or other blood products within the last three
             months, or injected or oral corticosteroids or other therapy expected to materially
             alter immune function within six weeks of the study vaccine. Individuals on a
             tapering dose schedule of oral steroids lasting less than 7 days may be included in
             the trial as long as they have not received more than one course within the last two
             weeks prior to enrollment.

          -  Received any vaccine in the 21-day period prior to enrollment or scheduled to receive
             any vaccination after enrollment and prior to visit 2.

          -  Suspected or known hypersensitivity to any of the vaccine components or to latex.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mercer Island</city>
        <state>Washington</state>
        <zip>98040-2758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sammamish</city>
        <state>Washington</state>
        <zip>98075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 28, 2012</lastchanged_date>
  <firstreceived_date>April 28, 2006</firstreceived_date>
  <firstreceived_results_date>September 28, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tetanus</keyword>
  <keyword>diphtheria</keyword>
  <keyword>acellular pertussis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 09 May 2006 to 02 October 2006 in 12 clinical centers in the US.</recruitment_details>
      <pre_assignment_details>A total of 647 participants who met the inclusion and exclusion criteria were enrolled, 644 were vaccinated and included in the analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adacel® Vaccine Group</title>
        </group>
        <group group_id="P2">
          <title>Boostrix® Vaccine Group</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="323"/>
                <participants group_id="P2" count="321"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="319"/>
                <participants group_id="P2" count="317"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adacel® Vaccine Group</title>
        </group>
        <group group_id="B2">
          <title>Boostrix® Vaccine Group</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="323"/>
                <measurement group_id="B2" value="321"/>
                <measurement group_id="B3" value="644"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="291"/>
                <measurement group_id="B2" value="291"/>
                <measurement group_id="B3" value="582"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="62"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="14.5" spread="2.33"/>
                <measurement group_id="B2" value="14.7" spread="2.33"/>
                <measurement group_id="B3" value="14.6" spread="2.33"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="154"/>
                <measurement group_id="B2" value="150"/>
                <measurement group_id="B3" value="304"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="169"/>
                <measurement group_id="B2" value="171"/>
                <measurement group_id="B3" value="340"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="323"/>
                <measurement group_id="B2" value="321"/>
                <measurement group_id="B3" value="644"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting A Solicited Injection Site or Systemic Reactions Within 7 Days Following Vaccination With Adacel® or Boostrix®</title>
        <description>Solicited injection site reactions: Pain, Erythema, and swelling. Solicited systemic reactions: Fever (temperature), Headache, Malaise, and Myalgia.
Grade 3 reaction definitions: Pain = Incapacitating, unable to perform usual activities; Erythema and swelling = ≥ 5 cm; Fever = temperature ≥ 39.1°C or ≥ 102.3°F; Headache, Malaise, and Myalgia = Prevents daily activities.</description>
        <time_frame>Day 0 to 7 post-vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Solicited injection site and Systemic reactions were analyzed in the intent-to-treat safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Adacel® Vaccine Group</title>
          </group>
          <group group_id="O2">
            <title>Boostrix® Vaccine Group</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="320"/>
                  <measurement group_id="O2" value="317"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting A Solicited Injection Site or Systemic Reactions Within 7 Days Following Vaccination With Adacel® or Boostrix®</title>
            <description>Solicited injection site reactions: Pain, Erythema, and swelling. Solicited systemic reactions: Fever (temperature), Headache, Malaise, and Myalgia.
Grade 3 reaction definitions: Pain = Incapacitating, unable to perform usual activities; Erythema and swelling = ≥ 5 cm; Fever = temperature ≥ 39.1°C or ≥ 102.3°F; Headache, Malaise, and Myalgia = Prevents daily activities.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any solicited injection site reaction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="273"/>
                  <measurement group_id="O2" value="257"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 solicited injection site reaction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any solicited injection site Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="270"/>
                  <measurement group_id="O2" value="247"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 solicited inj. site Pain (Incapacitating)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any solicited injection site Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="67"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 solicited injection site Erythema (≥ 5 cm)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any solicited injection site Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 solicited injection site Swelling (≥ 5 cm)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any solicited systemic reaction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="216"/>
                  <measurement group_id="O2" value="205"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 solicited systemic reaction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any solicited Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 solicited Fever (≥ 39.1°C or ≥ 102.3°F)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any solicited Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="136"/>
                  <measurement group_id="O2" value="108"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gr 3 solicited Headache: Prevents daily activities</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any solicited Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="91"/>
                  <measurement group_id="O2" value="78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gr 3 solicited Malaise: Prevents daily activities</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any solicited Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="167"/>
                  <measurement group_id="O2" value="166"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gr 3 solicited Myalgia: Prevents daily activities</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Tetanus Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination With Adacel® or Boostrix®.</title>
        <time_frame>Day 0 and 28 days post-vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Tetanus antitoxin concentrations were analyzed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Adacel® Vaccine Group</title>
          </group>
          <group group_id="O2">
            <title>Boostrix® Vaccine Group</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="305"/>
                  <measurement group_id="O2" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Tetanus Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination With Adacel® or Boostrix®.</title>
            <units>Percentage of Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Tetanus IgG antitoxin ≥0.1 IU/mL :pre-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99"/>
                  <measurement group_id="O2" value="98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Tetanus IgG antitoxin ≥0.1 IU/mL :28 days post-vac</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Diphtheria Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination With Adacel® or Boostrix®.</title>
        <time_frame>Day 0 and 28 days post-vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Diphtheria antitoxin concentrations were analyzed in the per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Adacel® Vaccine Group</title>
          </group>
          <group group_id="O2">
            <title>Boostrix® Vaccine Group</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="305"/>
                  <measurement group_id="O2" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Diphtheria Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination With Adacel® or Boostrix®.</title>
            <units>Percentage of Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Diphtheria IgG antitoxin ≥0.1 IU/mL : pre-vacc</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92"/>
                  <measurement group_id="O2" value="93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diphtheria IgG antitoxin ≥0.1 IU/mL: 28 D post-vac</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration of Antibody to Pertussis Antigens Pre- and Post-Vaccination With Adacel® or Boostrix®.</title>
        <time_frame>Day 0 and 28 days post-vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Geometric mean concentration of antibody to the pertussis antigens were analyzed in the per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Adacel® Vaccine Group</title>
          </group>
          <group group_id="O2">
            <title>Boostrix® Vaccine Group</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="305"/>
                  <measurement group_id="O2" value="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Concentration of Antibody to Pertussis Antigens Pre- and Post-Vaccination With Adacel® or Boostrix®.</title>
            <units>EU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-pertussis toxoid IgG: pre-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14.4" lower_limit="12.5" upper_limit="16.6"/>
                  <measurement group_id="O2" value="13.5" lower_limit="11.6" upper_limit="15.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-filamentous hemagglutinin IgG:pre-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26.1" lower_limit="22.7" upper_limit="30.0"/>
                  <measurement group_id="O2" value="28.2" lower_limit="24.5" upper_limit="32.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-pertactin IgG: pre-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.4" lower_limit="10.6" upper_limit="14.6"/>
                  <measurement group_id="O2" value="13.1" lower_limit="11.2" upper_limit="15.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-fimbriae types 2 and 3 IgG: pre-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.9" lower_limit="12.0" upper_limit="16.2"/>
                  <measurement group_id="O2" value="14.5" lower_limit="12.2" upper_limit="17.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-pertussis toxoid IgG: post-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="86.7" lower_limit="78.8" upper_limit="95.4"/>
                  <measurement group_id="O2" value="135.9" lower_limit="122.9" upper_limit="150.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-filamentous hemagglutinin IgG post-vaccinat.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="240.7" lower_limit="217.7" upper_limit="266.1"/>
                  <measurement group_id="O2" value="402.9" lower_limit="365.5" upper_limit="444.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-pertactin IgG: post-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="322.7" lower_limit="279.7" upper_limit="372.4"/>
                  <measurement group_id="O2" value="463.3" lower_limit="395.4" upper_limit="542.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-fimbriae types 2 and 3 IgG: post-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1203" lower_limit="1004" upper_limit="1442"/>
                  <measurement group_id="O2" value="26.6" lower_limit="22.2" upper_limit="31.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination up to 1 month post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adacel® Vaccine Group</title>
        </group>
        <group group_id="E2">
          <title>Boostrix® Vaccine Group</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="273" subjects_at_risk="320"/>
                <counts group_id="E2" subjects_affected="257" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Solicited injection site Pain</sub_title>
                <counts group_id="E1" subjects_affected="270" subjects_at_risk="320"/>
                <counts group_id="E2" subjects_affected="257" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Solicited injection site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="320"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Solicited injection site Swelling</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="320"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Solicited Fever</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="320"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="316"/>
              </event>
              <event>
                <sub_title>Solicited Malaise</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="320"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Solicited Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="320"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Solicited Headache</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="320"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUS@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
